What is Estarylla?
Estarylla is a combined oral contraceptive (COC) containing norgestimate 0.25 mg and ethinyl estradiol 0.035 mg, FDA-approved for pregnancy prevention in women of reproductive potential. 1
Formulation and Composition
Estarylla is a monophasic COC formulation containing:
- Active tablets (blue): 0.25 mg norgestimate + 0.035 mg ethinyl estradiol 1
- Placebo tablets (green): Inactive ingredients only 1
- Standard 28-day pack: 21 active hormone pills followed by 7 placebo pills 1
Mechanism of Action
Estarylla prevents pregnancy through multiple mechanisms:
- Primary mechanism: Inhibits ovulation by suppressing gonadotropin-releasing hormone, follicle-stimulating hormone, and luteinizing hormones 2
- Secondary effects: Alters cervical mucus and endometrial lining 2
Clinical Characteristics of Norgestimate
Norgestimate is a second-generation progestin with favorable properties:
- Minimal androgenic activity compared to first-generation progestins 3, 4
- Low impact on carbohydrate and lipid metabolism 4, 5
- Produces statistically significant increases in HDL cholesterol 4
- Associated with lower venous thromboembolism risk compared to some other COC formulations 6, 7
Non-Contraceptive Benefits
Beyond contraception, COCs containing norgestimate/ethinyl estradiol provide:
- Acne treatment: FDA-approved for moderate acne vulgaris, with 62% reduction in inflammatory lesions versus 38.6% with placebo 8
- Decreased menstrual cramping and blood loss 3
- Improvement in dysmenorrhea 3
- Protection against endometrial and ovarian cancers with >3 years use 3
- No increased risk of breast cancer 3
Safety Profile
Key safety considerations include:
- Completely reversible with no negative effect on long-term fertility 3
- Contraindicated in women with history of thromboembolic disease, stroke, myocardial infarction, or breast cancer 2
- Should not be used in breastfeeding women during first 3 weeks postpartum (Category 4) or generally during fourth week postpartum (Category 3) 9, 10
- Requires blood pressure monitoring at baseline and ongoing 2
Dosing and Administration
Standard regimen:
- One tablet daily at the same time each day 3
- Can be initiated within first 5 days of menstrual bleeding without backup contraception 9
- If started >5 days after bleeding begins, requires 7 days of backup contraception 9
Missed pill management:
- If <24 hours late: Take as soon as possible, no backup needed 3
- If 24-48 hours late: Take most recent missed pill, continue regular schedule, use backup contraception for 7 days 3
- If >48 hours late: Same as above, plus consider emergency contraception if unprotected intercourse occurred in previous 5 days during first week of pack 3
Common Adverse Effects
Expected side effects include: